Q3FY17 result: Abbott India
Bhagyashree Vivarekar / 06 Feb 2017
.jpg)
Abbott India Ltd. posted its Q3FY17 standalone results on February 6, 2017. The company’s standalone revenue for the quarter was Rs 756 crore, registering a marginal increase of 3.7 per cent QoQ.
Abbott India Ltd. posted its Q3FY17 standalone results on February 6, 2017. The company’s standalone revenue for the quarter was Rs 756 crore, registering a marginal increase of 3.7 per cent QoQ.
The company’s EBITDA for the quarter was Rs 123 crore, registering an increase of 17.5 per cent QoQ. The company's EBITDA margin 16.3 per cent, an expansion of 190 bps driven by fall in raw material expenses by 20.4 per cent QoQ.
The company's net profit was Rs 86 crore during the quarter, as against the net profit of Rs 75 crore in the previous quarter.
Abbott India is a phama company engaged in discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company’s primary operations include therapeutic care and specialty areas like neuroscience, metabolic and hospital care. Some of the brands developed by the company include Digene, Cremaffin, Epilex, Zolfresh Obimet, Brufen, Prothiaden, Ganaton, Sevorane, Thyronorm, Leptos and Survanta.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.